Factors modifying the migration of lymphocytes across the blood-brain barrier.
Characterising the factors that control the entry of leucocytes into tissue in response to inflammatory or microbial insult continues to generate considerable interest. Of all the tissues studied it is probably that of the CNS which is the most fascinating because of the specialised properties of its blood vessel walls, which constitute the blood-brain barrier (BBB). In health, very few leucocytes penetrate the BBB but in disorders such as MS the barrier becomes compromised with the result that there is an intense infiltration of the CNS by T lymphocytes whose subsequent activity appears to underlie the onset and progression of disease. The purpose of this article is to summarise and assess recent literature pertaining to how lymphocytes bind to cerebral endothelial cells, migrate across the blood vessel walls and enter the CNS parenchyma. Particular emphasis is devoted to the cellular and molecular aspects of these events and addressing the questions of whether certain subsets of circulating T lymphocytes are more favourably disposed than others to CNS infiltration and whether entry is dependent upon the initial expression of distinct groups of adhesion molecules and upon the generation of chemotactic factors. This article also focuses upon identifying the key stages of lymphocyte migration across the BBB and their susceptibility to antagonism by therapeutic agents. It is intended that the review will provide a useful source of information and offer additional insights into the mechanisms controlling lymphocyte passage across the BBB during pathological disturbance.
Brown
K A
KA
Department of Immunobiology, Guy's Hospital, London, UK.
D000818:Animals; D017951:Antigen Presentation; D001253:Astrocytes / Q000473:pathology; D001327:Autoimmune Diseases / Q000097:blood / Q000276:immunology / Q000473:pathology; D001812:Blood-Brain Barrier; D001921:Brain / Q000098:blood supply / Q000276:immunology; D002144:Callithrix; D002448:Cell Adhesion; D015815:Cell Adhesion Molecules / Q000502:physiology; D018925:Chemokines / Q000502:physiology; D002634:Chemotaxis, Leukocyte / Q000187:drug effects / Q000502:physiology*; D016207:Cytokines / Q000502:physiology; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000097:blood / Q000276:immunology / Q000473:pathology; D004730:Endothelium, Vascular / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D016326:Extracellular Matrix Proteins / Q000502:physiology; D005544:Forecasting; D006801:Humans; D007156:Immunologic Memory; D016130:Immunophenotyping; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D007371:Interferon-gamma / Q000378:metabolism; D007376:Interleukin-2 / Q000378:metabolism; D008213:Lymphocyte Activation; D008666:Metalloendopeptidases / Q000502:physiology; D051379:Mice; D008833:Microcirculation; D009103:Multiple Sclerosis / Q000097:blood / Q000276:immunology / Q000473:pathology; D009186:Myelin Sheath / Q000276:immunology / Q000473:pathology; D051381:Rats; D016176:T-Lymphocyte Subsets / Q000276:immunology / Q000378:metabolism / Q000473:pathology
D015815:Cell Adhesion Molecules; D018925:Chemokines; D016207:Cytokines; D016326:Extracellular Matrix Proteins; D007166:Immunosuppressive Agents; D007376:Interleukin-2; D007371:Interferon-gamma; D008666:Metalloendopeptidases